

Attruby™ (acoramidis)

What is Attruby?

Attruby is a TTR stabilizer developed for treating patients with transthyretin amyloidosis (ATTR) who have heart involvement (cardiomyopathy).

ATTR is caused by the weakening, separation and misfolding of a protein called transthyretin (TTR), followed by a build up in organs in the form of amyloid fibrils. When fibrils deposit in the heart, causing heart to stiffen, this is known as ATTR-CM. There are two different types of ATTR amyloidosis: one is caused by an inherited mutation, called hereditary ATTR (hATTR) or variant (ATTRv), and the other is not inherited, called wildtype ATTR (ATTRwt).

How does Attruby work?

Attruby is a drug that acts as TTR stabilizer. Attruby works by binding to the TTR protein and helping to stabilize that protein structure, preventing it from breaking down, misfolding, and forming amyloid fibrils. By stabilizing TTR and reducing the rate at which TTR misfolds, Attruby has the potential to limit amyloid formation and subsequently slow the progression of the disease.

How is Attruby administered?

Attruby is taken by mouth at 712 mg twice a day.

Clinical trial evidence for Attruby

In the randomized, double-blind, placebo controlled ATTRibute-CM Phase III clinical trial, 421 ATTR-CM patients received oral Attruby 800 mg twice a day for 30 months. Results from the trial have shown that, compared to those on placebo, patients who received Attruby resulted in a statistically significant better combined outcome that took in account death, hospitalization, biomarker and function.

Side effects of Attruby

Like all drugs, Attruby can cause side effects but was generally well tolerated. The most commonly observed side effects in clinical trials were cardiac failure, AFib, COVID-19, acute kidney injury, shortness of breath and constipation.

Availability of Attruby

Attruby was approved by the FDA on November 22, 2024 for the treatment of ATTR cardiomyopathy (ATTR-CM) in the United States.

Insurance coverage of Attruby will vary depending on the particular plan. If insurance does not provide enough coverage, there are patient assistance programs that will help. This includes BridgeBio's patient prescription assistance program, Forging Bridges.

You can learn more about this program on BridgeBio's website at forgingbridges.com or call 1-888-55-BRIDGE (1-888-552-7434).

Availability of Attruby

For more information you can visit us at www.arci.org. If you have further questions you can contact us by phone at 617-467-5170 or by email at support@arci.org.

